KALA Bio Signs Non-Binding LOI to Acquire Nationwide Telehealth Platform with Approximately $48 Million in Sales Since Inception
Key Highlights
- ➤Proposed acquisition valued at approximately $15 million, payable in cash and KALA stock
- ➤Target revenue $12.7 million for trailing twelve months ended August 2026, unaudited
- ➤Target served more than 90,000 clients across all 50 states since 2023
- ➤45-day due diligence period expected to conclude in November 2026
- ➤Closing targeted for late 2026 or early 2027, subject to approvals and definitive agreements
Expert Statements
Avi Minkowitz, Chief Executive Officer and Chief Financial Officer of KALA
“This transaction would add an established, revenue-generating platform to KALA's operating business, alongside our Virotek distribution program, with a direct channel to clients focused on preventative care and long-term health management.”
Avi Minkowitz, Chief Executive Officer and Chief Financial Officer of KALA
“We expect the Target's established revenue base to benefit KALA's growth in this business and across our other lines of business.”
Avi Minkowitz, Chief Executive Officer and Chief Financial Officer of KALA
“With more than 90,000 clients served since 2023, we see opportunities to grow the business, including by offering Virotek genetic testing through the platform and by exploring additional offerings.”
Avi Minkowitz, Chief Executive Officer and Chief Financial Officer of KALA
“We look forward to completing diligence and moving to definitive agreements. We are targeting closing in late 2026 or early 2027.”
Proposed Acquisition Valued at Approximately $15 Million Would Add an Established 50-State Telehealth Business, with over 90,000 clients, Focused on Peptides such as GLP-1 Weight Management, Hormone Health, Longevity and Sexual Wellness
Key Highlights * Target generated approximately $12.7 million in revenue for the trailing twelve months ended August 2026 (unaudited, as provided by Target management) and is cash-flow positive * Proposed purchase price of approximately $15 million, payable in cash and KALA stock; the cash portion is expected to be funded from existing balance sheet resources * Founded in 2023; LegitScript-certified, NABP-accredited platform serving clients in all 50 states; more than 90,000 clients served since inception * 45-day due diligence period expected to conclude in November 2026; definitive agreements and closing targeted for late 2026 or early 2027
Get started
Create a free account to read the full story.